AngioDynamics, Inc. (ANGO) EPS Estimated At $0.21

June 15, 2018 - By Peter Erickson

AngioDynamics, Inc. (NASDAQ:ANGO) LogoInvestors sentiment increased to 1.46 in 2018 Q1. Its up 0.20, from 1.26 in 2017Q4. It improved, as 17 investors sold AngioDynamics, Inc. shares while 40 reduced holdings. 25 funds opened positions while 58 raised stakes. 34.89 million shares or 2.93% more from 33.90 million shares in 2017Q4 were reported.
Smith Asset Mgmt Grp L P owns 10,871 shares. Great West Life Assurance Can holds 0% or 45,532 shares. Lapides Asset Mgmt Llc accumulated 427,100 shares or 1.62% of the stock. Eqis Capital Management stated it has 0.02% of its portfolio in AngioDynamics, Inc. (NASDAQ:ANGO). Citadel Advsr Ltd Limited Liability Company accumulated 139,824 shares. State Of Alaska Department Of Revenue invested in 11,828 shares or 0% of the stock. Aperio Grp Incorporated Ltd reported 11,127 shares or 0% of all its holdings. Fenimore Asset Management Inc reported 0.41% in AngioDynamics, Inc. (NASDAQ:ANGO). Mackay Shields Ltd Co holds 66,314 shares or 0.01% of its portfolio. 214,448 are owned by Jacobs Levy Equity Inc. Cornercap Counsel, Georgia-based fund reported 47,125 shares. Bailard holds 16,100 shares or 0.02% of its portfolio. Brinker Cap holds 12,898 shares or 0.01% of its portfolio. D E Shaw & Incorporated stated it has 0% of its portfolio in AngioDynamics, Inc. (NASDAQ:ANGO). First Tru Advsr L P owns 0% invested in AngioDynamics, Inc. (NASDAQ:ANGO) for 35,295 shares.

Analysts expect AngioDynamics, Inc. (NASDAQ:ANGO) to report $0.21 EPS on July, 17.They anticipate $0.02 EPS change or 10.53 % from last quarter’s $0.19 EPS. ANGO’s profit would be $7.73M giving it 25.77 P/E if the $0.21 EPS is correct. After having $0.25 EPS previously, AngioDynamics, Inc.’s analysts see -16.00 % EPS growth. The stock decreased 0.55% or $0.12 during the last trading session, reaching $21.65. About 87,925 shares traded. AngioDynamics, Inc. (NASDAQ:ANGO) has risen 30.75% since June 15, 2017 and is uptrending. It has outperformed by 18.18% the S&P500.

AngioDynamics, Inc. (NASDAQ:ANGO) Ratings Coverage

Among 3 analysts covering Angiodynamics (NASDAQ:ANGO), 1 have Buy rating, 0 Sell and 2 Hold. Therefore 33% are positive. Angiodynamics had 5 analyst reports since January 5, 2018 according to SRatingsIntel. The firm has “Outperform” rating by Raymond James given on Tuesday, April 3. The rating was maintained by Canaccord Genuity with “Hold” on Thursday, January 4. On Monday, April 2 the stock rating was maintained by Canaccord Genuity with “Hold”. Craig Hallum downgraded the stock to “Hold” rating in Friday, January 5 report. The stock of AngioDynamics, Inc. (NASDAQ:ANGO) has “Hold” rating given on Thursday, March 29 by Canaccord Genuity.

AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices for the treatment of peripheral vascular disease, vascular access, and for use in oncology and surgical settings in the United States and internationally. The company has market cap of $796.82 million. The firm provides manifolds, contrast management systems, closed fluid systems, guidewires, disposable transducers, and interventional accessories that help clinicians in the diagnosis and treatment of cardiovascular and peripheral vascular diseases; VenaCure EVLT laser system products to treat superficial venous diseases; Asclera drug for treating uncomplicated spider and reticular veins of the lower extremities; and Sotradecol drugs for treating small uncomplicated varicose veins of the lower extremities. It has a 601.39 P/E ratio. It also offers AngioVac venous drainage system that includes venous drainage cannula for the removal of fresh, soft thrombi, or emboli during extracorporeal bypass; and cardiopulmonary bypass circuit for use in procedures during extracorporeal circulatory support.

More news for AngioDynamics, Inc. (NASDAQ:ANGO) were recently published by: Benzinga.com, which released: “Benzinga’s Daily Biotech Pulse: Clinical Hold For Crispr, Gilead Study Meets Endpoint, Akers Gets Grace Time” on June 01, 2018. Nasdaq.com‘s article titled: “Research Report Identifies AngioDynamics, Kaiser Aluminum, Mammoth Energy Services, Meridian Bioscience …” and published on May 29, 2018 is yet another important article.

AngioDynamics, Inc. (NASDAQ:ANGO) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: